AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2466880
Drug: Prednisone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (20 mg every 8 hours for 48 hours)
Trial: 21292168
Drug: Alvimopan (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvimopan (both doses)
Trial: 9427984
Drug: 0.2 mg/ml
RxNorm normalized name: iodine 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/ml mitomycin-C
Trial: 9427984
Drug: 0.4 mg/ml
RxNorm normalized name: thymol 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/ml mitomycin-C
Trial: 3098341
Drug: 0.025 mg
RxNorm normalized name: lisuride 0.025 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025 mg transdermal oestradiol daily
Trial: 3098341
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg transdermal oestradiol daily
Trial: 3098341
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg transdermal oestradiol daily
Trial: 28186933
Drug: Diabetes Medication
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes Medication Choice Decision Aid
Trial: 25143179
Drug: Dermatology consultation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dermatology consultation (treatment group)
Trial: 15248230
Drug: Etanercept (interrupted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (interrupted therapy)
Trial: 12508476
Drug: Faropenem 300
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Faropenem 300 mg 3 times daily
Trial: 2680990
Drug: Enoxacin 400
RxNorm normalized name: enoxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin 400 mg b.i.d. for three days
Trial: 31481062
Drug: Parent-group treatment
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-group treatment focusing on evidence-based parenting practices
Trial: 16643234
Drug: ILIH block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ILIH block at 1 cm inferio‐medial to the anterior superior iliac spine (ASIS) with 0.25 ml/kg of 0.25% bupivacaine
Trial: 16643234
Drug: ILIH block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ILIH block at 1-2 cm medial to the ASIS with 0.25 ml/kg of 0.25% bupivacaine
Trial: 16643234
Drug: ILIH block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ILIH block at 2 cm superio‐medial to the ASIS with 0.25 ml/kg of 0.25% bupivacaine
Trial: 7988249
Drug: Postoperative thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative thoracic irradiation plus six cycles of CAP chemotherapy (cyclophosphamide, doxorubicin, and cisplatin)
Trial: 7988249
Drug: Postoperative thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative thoracic irradiation plus six cycles of CAP chemotherapy
Trial: 3385548
Drug: Group I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I: meperidine intramuscular
Trial: 3385548
Drug: Group II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II: atropine intramuscular and diazepam intravenous
Trial: 26249206
Drug: Insulin (INS,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (INS, n = 21)
Trial: 8175595
Drug: 0.3 g
RxNorm normalized name: sorbitol 0.3 GM Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g NaHCO3/kg body wt (alkalosis)
Trial: 8175595
Drug: 0.04 g
RxNorm normalized name: Glycerin 0.04 g in 1 g VAGINAL GEL [Inclear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 g NaCl/kg body wt (control)
Trial: 20625264
Drug: HIV-LIPO-5 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-LIPO-5 (all doses)
Trial: 18664477
Drug: Candesartan (on-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (on-treatment rate <360 fpm)
Trial: 18664477
Drug: Candesartan (on-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (on-treatment rate >360 fpm)
Trial: 14570722
Drug: 100 micro
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micro g octreotide
Trial: 10910488
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of ropivacaine 2 mg/ml (group 1)
Trial: 10910488
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of ropivacaine (both groups)
Trial: 8757206
Drug: Albuterol (QID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (QID + PRN)
Trial: 1558794
Drug: Mitoxantrone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (12 mg m‐2) administered via a 10 min i.v. infusion to 8 women (10 kinetics)
Trial: 1558794
Drug: High-dose mitoxantrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose mitoxantrone associated with high-dose alkylating agents administered to 7 women (7 kinetics)
Trial: 2862820
Drug: H3R3 (3‐times‐weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H3R3 (3‐times‐weekly isoniazid and rifampin up to 6 months)
Trial: 2862820
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with drug‐sensitive tubercle bacilli
Trial: 15985573
Drug: Testosterone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (100 mg T enanthate, weekly intramuscular injections)
Trial: 12974980
Drug: Sufentanil plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil plus magnesium infusion
Trial: 1894763
Drug: Control (aminophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (aminophylline 0.9 mg/kg/hr over 6 hours)
Trial: 30993680
Drug: Buccally absorbed
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccally absorbed prochlorperazine (BAP) 6 mg plus 2.25 mL saline IV placebo
Trial: 30993680
Drug: Intravenous prochlorperazine
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous prochlorperazine (IVP) 10 mg and buccally absorbed saccharine pill placebo
Trial: 30993680
Drug: Intravenous prochlorperazine
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous prochlorperazine (IVP)
Trial: 19114869
Drug: CD4 cell-driven
RxNorm normalized name: lisocabtagene maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD4 cell-driven scheduled treatment interruption (STI)
Trial: 9124839
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg)
Trial: 7694905
Drug: ECT three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECT three times weekly
Trial: 7694905
Drug: ECT twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECT twice weekly
Trial: 30242234
Drug: Muscle insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Muscle insulin sensitivity index (MISI)
Trial: 30242234
Drug: Hepatic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hepatic insulin resistance index (HIRI)
Trial: 15671129
Drug: Oral risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral risperidone 2‐6 mg/day
Trial: 29237679
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg once daily)
Trial: 2502789
Drug: Ethanol (0.56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.56 g/kg)
Trial: 12891223
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg twice daily)
Trial: 19920714
Drug: Diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (50 mg twice daily)
Trial: 12702550
Drug: Interleukin-2 (IL-2)
RxNorm normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 (IL-2) 225,000 IU twice daily for 30 days
Trial: 8877242
Drug: Ranitidine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine at a dose of 9.3 +/- 0.9 mg/kg/day
Trial: 1686656
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg remoxipride
Trial: 6628584
Drug: Becotide inhalation
RxNorm normalized name: BECOTIN CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Becotide inhalation
Trial: 6628584
Drug: Salbutamol pretreatment
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol pretreatment followed by Becotide inhalation
Trial: 31017637
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg orally twice daily
Trial: 30058377
Drug: Micronized dehydrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized dehydrated human amnion/chorion membrane (dHACM) injection
Trial: 21933851
Drug: Chemotherapy-only (intensification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-only (intensification and maintenance therapy; n = 186)
Trial: 21933851
Drug: Chemotherapy-only for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-only for patients with 11q23 aberrations (n = 49)
Trial: 9129064
Drug: zidovudine monotherapy
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zidovudine monotherapy
Trial: 7477798
Drug: Etomidate (0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.30 mg/kg IV induction, 0.02 mg/kg/min continuous infusion for 24-72 hours)
Trial: 7477798
Drug: Pentobarbital (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbital (not detailed in dosage or duration)
Trial: 2154925
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated oral rhesus Rotavirus candidate vaccine (strain MMU 18006 [lot RRV‐1])
Trial: 22848006
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (1000 mg testosterone undecanoate, n=33)
Trial: 17668541
Drug: Calcitriol 3
RxNorm normalized name: CALCITRIOL 3MCG/GM OINT,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 3 microg/g ointment
Trial: 15018018
Drug: Calcipotriol 50
RxNorm normalized name: Calcipotriol 50 microgram/g cutaneous cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 50 microg/g ointment
Trial: 15957724
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low dose oral midazolam (0.25 mg/kg) and low dose oral ketamine (3 mg/kg)
Trial: 12024143
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MRCP and EUS
Trial: 8580228
Drug: Phototherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phototherapy treatment for 1 week
Trial: 1265780
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 1g Podophyllum/day after irradiation (128 patients)
Trial: 25910800
Drug: Known AF
RxNorm normalized name: Canesten AF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Known AF without OAC treatment
Trial: 17107615
Drug: Antithrombin therapy
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin therapy
Trial: 1854075
Drug: Inhalation rewarming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation rewarming
Trial: 1854075
Drug: Inhalation rewarming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation rewarming and peripheral rewarming evaluated separately or in combination
Trial: 6889154
Drug: sulfisoxazole at
RxNorm normalized name: Sulfisoxazole
DrugBank: Sulfisoxazole (DB00263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulfisoxazole at 500 mg twice a day
Trial: 6889154
Drug: both pneumococcal
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: both pneumococcal vaccine and 500 mg sulfisoxazole twice daily
Trial: 6889154
Drug: no routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no routine medication
Trial: 6889154
Drug: antihistamines whenever
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antihistamines whenever nasally congested
Trial: 17765616
Drug: Metoprolol (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (n = 60, mean daily dose of 93 +/- 11 mg)
Trial: 15124719
Drug: Tongue‐muscle training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongue‐muscle training (20 minutes twice a day for 8 weeks)
Trial: 2596736
Drug: IV aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV aminophylline (6 mg/kg over fifteen minutes)
Trial: 28328148
Drug: XR-NTX (extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XR-NTX (extended-release naltrexone)
Trial: 19692680
Drug: Carboplatin-paclitaxel (carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin-paclitaxel (carboplatin dose calculated to produce an area under the curve of 5 or 6 mg per milliliter per minute plus paclitaxel 200 mg per square meter of body-surface area)
Trial: 16467543
Drug: Saw palmetto
RxNorm normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saw palmetto extract (160 mg twice a day)
Trial: 11130223
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care provided by clinical pharmacists
Trial: 25704652
Drug: Glimepiride (GL)
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride (GL) 3mg/d + ketotifen 1mg twice daily
Trial: 25704652
Drug: Glimepiride (GL)
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride (GL) 3mg/d + ketotifen 1mg once daily
Trial: 23143410
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (20 cc)
Trial: 23143410
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 cc 5% dextrose solution)
Trial: 9892449
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and medication clinic visits
Trial: 8670319
Drug: Correlation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation with growth hormone
Trial: 8670319
Drug: Correlation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation with growth hormone and glucagon
Trial: 2070058
Drug: Natural interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Natural interferon-alpha (nIFN-alpha) therapy at doses of 3 million IU, three times a week
Trial: 2070058
Drug: Recombinant interferon-alpha-2a
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon-alpha-2a (rIFN-alpha-2a) therapy
Trial: 24836312
Drug: Pirfenidone (2403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone (2403 mg per day)
Trial: 18269638
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart (BIAsp) thrice-daily regimen
Trial: 18269638
Drug: Biphasic human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic human insulin (BHI) 30 group
Trial: 10484801
Drug: Dexamethasone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.2 mg/kg)
Trial: 1448739
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (750 milligrams) prophylactic cefamandole delivered directly into the operative wound with local anesthesia
Trial: 8419612
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone therapy
Trial: 26527204
Drug: Oral appliances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral appliances (OAs)
Trial: 23867247
Drug: Xifeng Dingchan
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xifeng Dingchan Pill (XFDCP) with Madopar for early-stage PD (n = 80)
Trial: 23867247
Drug: Xifeng Dingchan
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xifeng Dingchan Pill (XFDCP) combined with Madopar and Piribedil for middle-stage PD (n = 80)
Trial: 9184388
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant hirudin (HBW 023)
Trial: 1530173
Drug: 0.25% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% ropivacaine (112.5 mg)
Trial: 1530173
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine (112.5 mg)
Trial: 17977950
Drug: Pioglitazone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone treatment for 16 weeks
Trial: 20921315
Drug: Tigecycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tigecycline (100 mg loading dose followed by 50 mg every 12 hours)
Trial: 12049012
Drug: Conventional absorbable
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional absorbable subcutaneous Polyglactin 910 (VICRYL, ETHICON) and non absorbable cutaneous Monofilament Nylon (ETHILON, ETHICON) stitches
Trial: 12049012
Drug: Running subcutaneous
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Running subcutaneous and intradermic irradiated Polyglactin 910/370 (VICRYL‐Rapide, ETHICON) sutures
Trial: 7945744
Drug: Apomorphine (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (0.01 mg/kg SC)
Trial: 7945744
Drug: MK-212 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-212 (20 mg PO)
Trial: 3111514
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg orally four times daily for 4 days
Trial: 3111514
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg orally twice daily for 4 days
Trial: 3111514
Drug: Glibenclamide administered
RxNorm normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glibenclamide administered alone
Trial: 15705011
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER (75 to 225 mg/day)
Trial: 9424681
Drug: d‐tubocurarine 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐tubocurarine 0.05 mg/kg
Trial: 30445999
Drug: Letrozole (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (oral fertility medication)
Trial: 27902622
Drug: Penetration acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penetration acupuncture treatment on head combined with conventional treatment (treatment group [TG])
Trial: 27902622
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment only (control group [CG])
Trial: 16595599
Drug: Metformin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1 g twice daily)
Trial: 16154855
Drug: Daily 3-hour
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily 3-hour fast infusions of arsenic trioxide (As2O3)
Trial: 16154855
Drug: Daily slow,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily slow, continuous infusions of arsenic trioxide (As2O3)
Trial: 9170398
Drug: No calcium
RxNorm normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No calcium antagonist
Trial: 31356878
Drug: ASP7962 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP7962 (100 mg BID)
Trial: 12017396
Drug: naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen (500 mg BID)
Trial: 30146144
Drug: Structured Cognitive-Behavioral
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured Cognitive-Behavioral Therapy (CBT)
Trial: 30146144
Drug: Less-Structured Cognitive-Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less-Structured Cognitive-Behavioral Therapy (CBT)